Patritumab
HER3 | |
|---|---|
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
Patritumab (
INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.[1][2]
Clinical trials
It is in a phase 2 clinical trial for
squamous cell cancer of the head and neck.[3]
It is to be included in a new arm of the
I-SPY 2 breast cancer trial.[4]
References
- ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
- S2CID 4035336.
- ^ Clinical trial number NCT02633800 for "A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck" at ClinicalTrials.gov
- ^ "Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer". October 2016.